C4 Therapeutics (CCCC) Current Assets (2019 - 2026)

C4 Therapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $245.4 million for Q1 2026.

• In Q1 2026, Current Assets rose 5.52% year-over-year to $245.4 million; the TTM figure through Mar 2026 stood at $245.4 million (up 5.52% YoY), while the FY2025 annual figure was $258.1 million, changed 0.13% from the prior year.
• Current Assets was $245.4 million for Q1 2026 at C4 Therapeutics, down from $258.1 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $325.5 million in Q3 2022 to a low of $206.9 million in Q3 2025.
• Historically, Current Assets has averaged $266.8 million across 5 years, with a median of $273.2 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Current Assets slumped 33.34% in 2022, then advanced 22.15% in 2024.
• A 5-year view of Current Assets shows it stood at $287.6 million in 2022, then retreated by 5.69% to $271.2 million in 2023, then fell by 4.95% to $257.8 million in 2024, then grew by 0.13% to $258.1 million in 2025, then slipped by 4.94% to $245.4 million in 2026.
• The last three Current Assets figures came in at $245.4 million (Q1 2026), $258.1 million (Q4 2025), and $206.9 million (Q3 2025), per Business Quant data.